Abstract
Expression levels of biomarkers are generally unknown at initial diagnosis. The development of theranostic probes that do not rely on biomarker availability would expand therapy options for cancer patients, improve patient selection for nanomedicine and facilitate treatment of inoperable patients or patients with acquired therapy resistance. Herein, we report the development of star polymers, also known as nanostars, that allow for molecular imaging and/or endoradiotherapy based on passive targeting via the enhanced permeability and retention (EPR) effect.
Original language | English |
---|---|
Pages (from-to) | 567-584 |
Number of pages | 18 |
Journal | Theranostics |
Volume | 10 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2020 |
Open Access - Access Right Statement
© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.Keywords
- biochemical markers
- magnetic resonance imaging
- nanoparticles
- star-branched polymers
- tumors